LP-168 / Lupeng Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LP-168 / Lupeng Pharma
NCT05432713: A Study of LP-168 in Healthy Volunteers

Completed
1
70
RoW
LP-168 tablet, NWP-775, LP-168 Placebo tablet, NWP-775 Placebo
Guangzhou Lupeng Pharmaceutical Company LTD.
Multiple Sclerosis, NMO Spectrum Disorder
11/22
12/22
LP-168-US-I01, NCT04775745: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Recruiting
1
60
US
LP-168
Newave Pharmaceutical Inc
CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Hairy Cell Leukemia
07/25
12/25
NCT05917964: A Food Effect Study of LP-168 Tablets in Healthy Subjects

Completed
1
22
RoW
LP-168 tablet, NWP-775
Guangzhou Lupeng Pharmaceutical Company LTD.
Mantle Cell Lymphoma
08/23
08/23
NCT06126861: The Mass Balance Study of LP-168 in Healthy Subjects

Completed
1
6
RoW
[14C]LP-168
Guangzhou Lupeng Pharmaceutical Company LTD.
Clinical Pharmacology
02/24
03/24
NCT04993690: A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

Recruiting
1
156
RoW
LP-168 tablet
Guangzhou Lupeng Pharmaceutical Company LTD.
B-cell Lymphoma
12/23
06/24
LP-168-CN301, NCT06251180: Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

Recruiting
1
112
RoW
Rocbrutinib, LP-168, Rituximab, MabThera; Rituximab Biosimilar HLX01; Rituximab biosimilar TQB2303; Henlius; Halpryza, Cyclophosphamide, CTX, doxorubicin, ADM; Adriamycin; DOX; Doxorubin hydrochloride, Vincristin, VCR; Vincrystine, Prednisone, delta.1-Cortisone; 1, 2-Dehydrocortisone
Guangzhou Lupeng Pharmaceutical Company LTD.
B-cell Non-Hodgkin Lymphoma
12/24
12/29

Download Options